<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30311421</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>12</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">2045-7634</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>12</Day>                    </PubDate>                </JournalIssue>                <Title>Cancer medicine</Title>                <ISOAbbreviation>Cancer Med</ISOAbbreviation>            </Journal>            <ArticleTitle>Clinical implication of subcategorizing T2 category into T2a and T2b in TNM staging of breast cancer.</ArticleTitle>            <ELocationID EIdType="doi" ValidYN="Y">10.1002/cam4.1831</ELocationID>            <Abstract>                <AbstractText>Regarding TNM staging in breast cancer, T2 category is currently not divided into subcategories even though it covers a wider range of tumor sizes than T1 category. Using Korean Breast Cancer Registry database, data of 41 071 women diagnosed as non-metastatic T2 breast cancer between 2001 and 2014 were analyzed. Cutoff value for optimal tumor size was approximated by receiver operating characteristic (ROC) curve to subcategorize T2 tumors. Overall survival (OS) was compared between two subcategories. Median follow-up period was 65 months. Of 41 071 patients, 4504 (11.0%) died. Based on ROC curve analysis, 3.0 cm was selected as the cutoff value. Five-year OS rate was 91% in patients with breast tumors ≤3.0 cm (T2a) and 86% in patients with breast tumors &gt;3.0 cm (T2b) (log-rank P &lt; 0.001). T2b subcategory showed worse OS than T2a subcategory regardless of node status (log-rank P &lt; 0.001 for all node categories). Within every subgroup defined by primary OS analysis covariates, T2b subcategory consistently showed worse outcome compared to T2a subcategory. By multivariate analysis, T2b subcategory was a significant independent prognostic factor of OS (hazard ratio: 1.26, 95% CI = 1.18-1.34). T2 category of breast cancer could be subcategorized into T2a and T2b with a cutoff value of 3 cm. These subcategories definitely showed different OSs even after adjusted for known prognostic factors. Subcategorization of T2 category might be useful for predicting prognosis more accurately and tailoring adjuvant therapy.</AbstractText>                <CopyrightInformation>© 2018 The Authors. Cancer Medicine published by John Wiley &amp; Sons Ltd.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Jung</LastName>                    <ForeName>Jiwoong</ForeName>                    <Initials>J</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0003-4146-6475</Identifier>                    <AffiliationInfo>                        <Affiliation>Department of Surgery, Seoul Medical Center, Seoul, Korea.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Suh</LastName>                    <ForeName>Young Jin</ForeName>                    <Initials>YJ</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Surgery, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Suwon, Korea.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ko</LastName>                    <ForeName>Byung Kyun</ForeName>                    <Initials>BK</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Surgery, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Lee</LastName>                    <ForeName>Eun Sook</ForeName>                    <Initials>ES</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0003-1122-8230</Identifier>                    <AffiliationInfo>                        <Affiliation>Center for Breast Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Korea.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Kim</LastName>                    <ForeName>Eun-Kyu</ForeName>                    <Initials>EK</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Paik</LastName>                    <ForeName>Nam Sun</ForeName>                    <Initials>NS</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Surgery, Ewha Womans University Mokdong Hospital, Ewha Womans University College of Medicine, Seoul, Korea.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Byun</LastName>                    <ForeName>Kyung Do</ForeName>                    <Initials>KD</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Surgery, Dong-A University Medical Center, Dong-A University College of Medicine, Busan, Korea.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Hwang</LastName>                    <ForeName>Ki-Tae</ForeName>                    <Initials>KT</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0001-6597-3119</Identifier>                    <AffiliationInfo>                        <Affiliation>Department of Surgery, Seoul National University Boramae Medical Center, Seoul, Korea.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Cancer Med</MedlineTA>            <NlmUniqueID>101595310</NlmUniqueID>            <ISSNLinking>2045-7634</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">TNM staging</Keyword>            <Keyword MajorTopicYN="N">breast neoplasms</Keyword>            <Keyword MajorTopicYN="N">prognosis</Keyword>            <Keyword MajorTopicYN="N">tumor staging</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>07</Month>                <Day>19</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>08</Month>                <Day>27</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>09</Month>                <Day>24</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>13</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>13</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>13</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30311421</ArticleId>            <ArticleId IdType="doi">10.1002/cam4.1831</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>